Roth et al. [44] performed an in vitro study to investigate the impact of omalizumab administered at 0.1 μg/mL, 0.5 μg/mL, and 1.0 μg/mL on primary human ASMCs isolated from allergic asthma donors and stimulated with IgE 1 μg/mL. The gene discussed is IGHE; the disease is allergic asthma.